ALK and cancer: In contrast to the first and second generations of ALK inhibitors, treatment resistance in the case of lorlatinib is not driven by ALK (acquired) point mutations but is instead driven by the pathway evasion strategies of the cancer cells, namely through the PI3K-Akt-mTOR and the RAS/MAPK pathways.